With our Artificial Intelligence (AI) based platform, AtomNet® technology, we work on some of the most challenging steps in drug discovery.
Together we will identify hit compounds and clinical leads.Learn More
Artificial Intelligence Molecular Screen (AIMS) Awards program, created and tailored to support academic researchers.Learn More
Together we will identify the targets of a phenotypic screen.Learn More
Our industry-leading AI technology can predict billions of small molecule protein interactions to help you discover novel compounds for hit and lead optimizations. We can easily customize analysis to suit your needs. Partners value our team’s flexible and fast process, and that’s why some of the world’s top pharma companies and universities keep coming back to work with us.Partner with Us
We can identify hit compounds for your target protein. Atomwise will drastically reduce your physical screening efforts and help you identify leads without having to synthesize or buy large libraries of compounds.
We screen billions of small molecules with diverse chemical structures and identify a handful of chemical scaffolds that are predicted to selectively bind to your target protein. We use the physical or predicted structure of your target protein and binding pocket for initial screening (using our classification model). We screen millions of compounds to generate a list of quality hits in just a few weeks. We can perform counter-screens against other targets and narrow the pool of hits for desirable properties such as oral bioavailability or blood brain barrier permeability. We can use data from your standard assays to optimize our model for your target protein.
We help you explore the chemical space around a handful of chemical scaffolds identified in hit discovery. We work with you to generate a list of compounds for each chemical scaffold. We screen the lists and then help you build a focused library ready for lead optimization.
Lead optimization doesn’t have to be the hardest or most expensive step in drug discovery. By leveraging our AI platform, we help you jump each hurdle in lead optimization, from potency to selectivity to ADME-Tox. What’s more, we will set you up for success in both animal and human trials by screening for toxicity in each model.
We can optimize for potency by screening (using a QSAR model) your focused library or a virtual focused library that we build together to reduce the size of your library and identify the most potent lead compounds.
We can optimize for selectivity and ADME-Tox. If we haven’t already addressed absorption at an early stage, we can filter your library for compounds with oral bioavailability, cell or BBB permeability, or any other parameter you like. We can optimize for other ADME-Tox properties, such as survival on first pass through the liver, cardiac toxicity (e.g. no hERG binding), and degradation by cytochrome P450 enzymes. We can help you identify patentable leads through the use of scaffold-hopping.
We can help you discover the mechanism of action. Two common ways that our partners ask for our help include:
What challenging target do you want to drug?Learn More About Partnering With Atomwise